Gallbladder cancer in the 21st century

Journal of Oncology

Volumn 2015, Issue , 2015, Pages

  Kanthan, Rani ^a   Senger, Jenna Lynn ^b   Ahmed, Shahid ^c   Kanthan, Selliah Chandra ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOSQUAMOUS CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLELITHIASIS; CHRONIC INFLAMMATION; CLEAR CELL ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRIBRIFORM CARCINOMA; CYTOPATHOLOGY; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; GALLBLADDER CANCER; GALLBLADDER POLYP; GALLBLADDER SARCOMA; GALLBLADDER TUMOR; HELICOBACTER INFECTION; HEPATOID ADENOCARCINOMA; HISTOPATHOLOGY; HUMAN; MANAGEMENT; MOLECULAR PATHOLOGY; MUCINOUS ADENOCARCINOMA; NEUROENDOCRINE TUMOR; PAPILLARY ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIGNET RING CARCINOMA; SQUAMOUS CELL CARCINOMA; SURGICAL PATIENT; SYSTEMIC THERAPY; UNDIFFERENTIATED CARCINOMA;

EID: 84941730116     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2015/967472     Document Type: Review

References (169)

1. C. H. E. Lai andW. Y. Lau, "Gallbladder cancer-A comprehensive review," Surgeon, vol. 6, no. 2, pp. 101-110, 2008.
2. A. X. Zhu, T. S. Hong, A. F. Hezel, and D. A. Kooby, "Current management of gallbladder carcinoma," The Oncologist, vol. 15, no. 2, pp. 168-181, 2010.
3. U. Dutta, "Gallbladder cancer: can newer insights improve the outcome" Journal of Gastroenterology and Hepatology, vol. 27, no. 4, pp. 642-653, 2012.
4. C. Ramos-Font, M. Gomez-Rio, A. Rodŕguez-Fernández, A. Jiménez-Heffernan, R. S. Sánchez, and J. M. Llamas-Elvira, "Ability of FDG-PET/CT in the detection of gallbladder cancer," Journal of Surgical Oncology, vol. 109, no. 3, pp. 218-224, 2014.
5. GallbladderCancer,AmericanCancerSociety, 2015, http://www .cancer.org/acs/groups/cid/documents/webcontent/003101-pdf .pdf.
6. G. Miller and W. R. Jarnagin, "Gallbladder carcinoma," European Journal of Surgical Oncology, vol. 34, no. 3, pp. 306-312, 2008.
7. R. Hundal and E. A. Shaffer, "Gallbladder cancer: epidemiology and outcome," Clinical Epidemiology, vol. 6, no. 1, pp. 99-109, 2014.
8. S. P. Kaushik, "Current perspectives in gallbladder carcinoma," Journal of Gastroenterology and Hepatology, vol. 16, no. 8, pp. 848-854, 2001.
9. T. Rustagi andC. A. Dasanu, "Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates," Journal of Gastrointestinal Cancer, vol. 43, no. 2, pp. 137-147, 2012.
10. A. Vijayakumar, A. Vijayakumar, V. Patil, M. N. Mallikarjuna, and B. S. Shivaswamy, "Early diagnosis of gallbladder carcinoma: an algorithm approach," ISRN Radiology, vol. 2013, Article ID 239424, 6 pages, 2013.
11. D.Hariharan, A. Saied, andH.M.Kocher, "Analysis ofmortality rates for gallbladder cancer across the world," HPB, vol. 10, no. 5, pp. 327-331, 2008.
12. A. Cariati, E. Piromalli, and F. Cetta, "Gallbladder cancers: associated conditions, histological types, prognosis, and prevention," European Journal of Gastroenterology and Hepatology, vol. 26, no. 5, pp. 562-569, 2014.
13. K. Y.Wolin, K. Carson, and G. A. Colditz, "Obesity and cancer," The Oncologist, vol. 15, no. 6, pp. 556-565, 2010.
14. C. Seretis, E. Lagoudianakis, G. Gemenetzis, F. Seretis, A. Pappas, and S. Gourgiotis, "Metaplastic changes in chronic cholecystitis: implications for early diagnosis and surgical intervention to prevent the gallbladder metaplasia-dysplasiacarcinoma sequence," Journal of ClinicalMedicine Research, vol. 6, no. 1, pp. 26-29, 2014.
15. R. Wiles, M. Varadpande, S. Muly, and J. Webb, "Growth rate and malignant potential of small gallbladder polyps-systematic review of evidence," Surgeon, vol. 12, no. 4, pp. 221-226, 2014.
16. G. Donald, D. Sunjaya, T. Donahue, and O. Joe Hines, "Polyp on ultrasound: now what? the association between gallbladder polyps and cancer," The American Surgeon, vol. 79, no. 10, pp. 1005-1008, 2013.
17. A. Maydeo and V. Dhir, "The gallbladder polyp conundrum: a riddler on the wall," Gastrointestinal Endoscopy, vol. 78, no. 3, pp. 494-495, 2013.
18. ? A. Andrén-Sandberg and Y. Deng, "Aspects on gallbladder cancer in 2014," Current Opinion in Gastroenterology, vol. 30, no. 3, pp. 326-331, 2014.
19. S. Basu, M. K. Singh, T. B. Singh, S. K. Bhartiya, S. P. Singh, and V. K. Shukla, "Heavy and trace metals in carcinoma of the gallbladder," World Journal of Surgery, vol. 37, no. 11, pp. 2641-2646, 2013.
20. K. S. Lim, C. C. Peters,A.Kow, and C. H. Tan, "The varying faces of gall bladder carcinoma: pictorial essay," Acta Radiologica, vol. 53, no. 5, pp. 494-500, 2012.
21. K. Yoshimitsu, Y. Nishihara, D. Okamoto et al., "Magnetic resonance differentiation between T2 and T1 gallbladder carcinoma: significance of subserosal enhancement on the delayed phase dynamic study," Magnetic Resonance Imaging, vol. 30, no. 6, pp. 854-859, 2012.
22. T. Wakai, Y. Shirai, J. Sakata, M. Nagahashi, Y. Ajioka, and K. Hatakeyama, "Mode of hepatic spread from gallbladder carcinoma: an immunohistochemical analysis of 42 hepatectomized specimens,"The American Journal of Surgical Pathology, vol. 34, no. 1, pp. 65-74, 2010.
23. S. K. Maurya, M. Tewari, R. R. Mishra, and H. S. Shukla, "Genetic aberrations in gallbladder cancer," Surgical Oncology, vol. 21, no. 1, pp. 37-43, 2012.
24. I. Roa, X. De Aretxabala, J. C. Araya, and J. Roa, "Preneoplastic lesions in gallbladder cancer," Journal of Surgical Oncology, vol. 93, no. 8, pp. 615-623, 2006.
25. N. R. Hughes and P. S. Bhathal, "Adenocarcinoma of gallbladder: an immunohistochemical profile and comparison with cholangiocarcinoma," Journal of Clinical Pathology, vol. 66, no. 3, pp. 212-217, 2013.
26. R. D. Goldin and J. C. Roa, "Gallbladder cancer: a morphological and molecular update," Histopathology, vol. 55, no. 2, pp. 218-229, 2009.
27. L. Solaini, A. Sharma, J. Watt, S. Iosifidou, J.-A. Chin Aleong, and H.M. Kocher, "Predictive factors for incidental gallbladder dysplasia and carcinoma," Journal of Surgical Research, vol. 189, no. 1, pp. 17-21, 2014.
28. R. Kanthan, J.-L. Senger, and S. C. Kanthan, "Molecular events in primary and metastatic colorectal carcinoma: a review," Pathology Research International, vol. 2012, Article ID 597497, 14 pages, 2012.
29. T. Kuroki, Y. Tajima, K. Matsuo, and T. Kanematsu, "Genetic alterations in gallbladder carcinoma," Surgery Today, vol. 35,no. 2, pp. 101-105, 2005.
30. M. Li, Z. Zhang, X. Li et al., "Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway," Nature Genetics, vol. 46, no. 8, pp. 872-876, 2014.
31. N. Kumari, V. K. Kapoor, N. Krishnani, K. Kumar, and D. K. Baitha, "Role of c-erbB2 expression in gallbladder cancer," Indian Journal of Pathology and Microbiology, vol. 55, no. 1, pp. 75-79, 2012.
32. S.-N. Wang, S.-C. Chung, K.-B. Tsai et al., "Aberrant p53 expression and the development of gallbladder carcinoma and adenoma," Kaohsiung Journal of Medical Sciences, vol. 22, no. 2, pp. 53-59, 2006.
33. H.-B. Ma, H.-T. Hu, Z.-L. Di et al., "Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma," World Journal of Gastroenterology, vol. 11, no. 5, pp. 744-747, 2005.
34. Z. Yang, Z. Yang, L. Xiong et al., "Expression of VHL and HIF-1 and their clinicopathologic significance in benign and malignant lesions of the gallbladder," Applied Immunohistochemistry and Molecular Morphology, vol. 19, no. 6, pp. 534-539, 2011.
35. S. Yi, Z.-L. Yang, X. Miao et al., "N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas," Pathology Research and Practice, vol. 210, no. 6, pp. 363-368, 2014.
36. M. Ghosh, H. Kamma, T. Kawamoto et al., "MUC1 core protein as a marker of gallbladder malignancy," European Journal of Surgical Oncology, vol. 31, no. 8, pp. 891-896, 2005.
37. P. Letelier, P. Garcia, P. Leal et al., "Immunohistochemical expression of vascular endothelial growth factor a in advanced gallbladder carcinoma," Applied Immunohistochemistry and Molecular Morphology, vol. 22, no. 7, pp. 530-536, 2014.
38. M. Tewari, A. Agarwal, R. R. Mishra, R. N. Meena, and H. S. Shukla, "Epigenetic changes in carcinogenesis of gallbladder," Indian Journal of Surgical Oncology, vol. 4, no. 4, pp. 356-361, 2013.
39. M. G. House, I. I.Wistuba, P. Argani et al., "Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer," Annals of Surgical Oncology, vol. 10, no. 8, pp. 882-889, 2003.
40. A. P. Moy, M. Shahid, C. R. Ferrone et al., "Microsatellite instability in gallbladder carcinoma," Virchows Archiv, vol. 466, pp. 393-402, 2015.
41. K.Wu,M. Liao, B. Liu, and Z.Deng, "ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients," Medical Oncology, vol. 28, no. 2, pp. 475-480, 2011.
42. ? A. Andrén-Sandberg, "Molecular biology of gallbladder cancer: potential clinical implications," North American Journal of Medical Sciences, vol. 4, no. 10, pp. 435-441, 2012.
43. Q. Zou, L. Xiong, Z. Yang, F. Lv, L. Yang, and X. Miao, "Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder," World Journal of Surgical Oncology, vol. 10, article 92, 2012.
44. J. E. Nevin, T. H. Moran, S. Kay, and R. King, "Carcinoma of gallbladder," Cancer, vol. 37, no. 1, pp. 141-148, 1976.
45. H. Onoyama,M. Yamamoto, A. Tseng, T. Ajiki, and Y. Saitoh, "Extended cholecystectomy for carcinoma of the gallbladder," World Journal of Surgery, vol. 19, no. 5, pp. 758-763, 1995.
46. AJCC, "Gallbladder," in AJCC Cancer Staging Manual, S. B. Edge, D. R. Byrd, C. C. Compton et al., Eds., pp. 211-217, Springer, NewYork, NY,USA, 7th edition, 2010.
47. K. Jin, H. Lan, T. Zhu, K. He, and L. Teng, "Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it," Clinical and Translational Oncology, vol. 13, no. 1, pp. 25-33, 2011.
48. S. R.Grobmyer, M. D. Lieberman, and J.M.Daly, "Gallbladder cancer in the twentieth century: single institution's experience," World Journal of Surgery, vol. 28, no. 1, pp. 47-49, 2004.
49. K. Inui, J. Yoshino, and H. Miyoshi, "Diagnosis of gallbladder tumors," Internal Medicine, vol. 50, no. 11, pp. 1133-1136, 2011.
50. W.-B. Choi, S.-K. Lee, M.-H. Kim et al., "A new strategy to predict the neoplastic polyps of the gallbladder based on a scoring system using EUS," Gastrointestinal Endoscopy, vol. 52, no. 3, pp. 372-379, 2000.
51. J.-H. Choi, D.-W. Seo, J. H. Choi et al., "Utility of contrastenhanced harmonic EUS in the diagnosis ofmalignant gallbladder polyps (with videos)," Gastrointestinal Endoscopy, vol. 78, no. 3, pp. 484-493, 2013.
52. S. C. Mayo, A. D. Shore, H. Nathan et al., "National trends in themanagement and survival of surgicallymanaged gallbladder adenocarcinoma over 15 years: a population-based analysis," Journal of Gastrointestinal Surgery, vol. 14, no. 10, pp. 1578-1591, 2010.
53. S. D. Deshmukh, P. T. Johnson, S. Sheth, R. Hruban, and E. K. Fishman, "CT of gallbladder cancer and its mimics: a patternbased approach," Abdominal Imaging, vol. 38,no. 3, pp. 527-536, 2013.
54. S. J. Kim, J. M. Lee, E. S. Lee, J. K. Han, and B. I. Choi, "Preoperative staging of gallbladder carcinoma using biliary MR imaging," Journal of Magnetic Resonance Imaging, vol. 41, no. 2, pp. 314-321, 2015.
55. N. K. Lee, S. Kim, T. U. Kim, D. U. Kim, H. I. Seo, and T. Y. Jeon, "Diffusion-weighted MRI for differentiation of benign from malignant lesions in the gallbladder," Clinical Radiology, vol. 69, no. 2, pp. e78-e85, 2014.
56. S. J. Kim, J. M. Lee, H. Kim, J. H. Yoon, J. K. Han, and B. I. Choi, "Role of diffusion-weighted magnetic resonance imaging in the diagnosis of gallbladder cancer," Journal of Magnetic Resonance Imaging, vol. 38, no. 1, pp. 127-137, 2013.
57. Q.Ke, Z. L. He,X.Duan, and S. S.Zheng, "Chronic cholecystitis with hilar bile duct stricture mimicking gallbladder carcinoma on positron emission tomography: a case report,"Molecular and Clinical Oncology, vol. 1, no. 3, pp. 517-520, 2013.
58. R. Yadav, D. Jain, S. R. Mathur, A. Sharma, and V. K. Iyer, "Gallbladder carcinoma: an attempt of WHO histological classification on fine needle aspiration material," CytoJournal, vol. 10, article 12, 2013.
59. M.-J. Kim, K. W. Kim, H.-C. Kim et al., "Unusual malignant tumors of the gallbladder," American Journal of Roentgenology, vol. 187, no. 2, pp. 473-480, 2006.
60. T. H. Giang, T. T. B. Ngoc, and L. A. Hassell, "Carcinoma involving the gallbladder: a retrospective review of 23 cases-pitfalls in diagnosis of gallbladder carcinoma," Diagnostic Pathology, vol. 7, article 10, 2012.
61. H.Kijima,Y.Wu, T.Yosizawa et al., "Pathological characteristics of early to advanced gallbladder carcinoma and extrahepatic cholangiocarcinoma," Journal of Hepato-Biliary-Pancreatic Sciences, vol. 21, no. 7, pp. 453-458, 2014.
62. J. Albores-Saavedra,M. Tuck, B. K.McLaren, K. S. Carrick, and D. E. Henson, "Papillary carcinomas of the gallbladder: analysis of noninvasive and invasive types," Archives of Pathology and Laboratory Medicine, vol. 129, no. 7, pp. 905-909, 2005.
63. N. Dursun, O. T. Escalona, J. C. Roa et al., "Mucinous carcinomas of the gallbladder. Clinicopathologic analysis of 15 cases identified in 606 carcinomas," Archives of Pathology and Laboratory Medicine, vol. 136, no. 11, pp. 1347-1358, 2012.
64. J. C. Roa, O. Tapia, A. Cakir et al., "Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas," Modern Pathology, vol. 24, no. 8, pp. 1069-1078, 2011.
65. Y.Oohashi, Y. Shirai, T. Wakai, S. Nagakura,H.Watanabe, and K. Hatakeyama, "Adenosquamous carcinoma of the gallbladder warrants resection only if curative resection is feasible," Cancer, vol. 94, no. 11, pp. 3000-3005, 2002.
66. J. Albores-Saavedra, D. E. Henson, D. Moran-Portela, and S. Lino-Silva, "Cribriform carcinoma of the gallbladder: a clinicopathologic study of 7 cases," American Journal of Surgical Pathology, vol. 32, no. 11, pp. 1694-1698, 2008.
67. S. Ellouze, C. Slim, G. Ahmad et al., "Hepatoid adenocarcinoma of the gallbladder," World Journal of Surgical Oncology, vol. 9, article 103, 2011.
68. A. Bittinger, I. Altekruger, P. Barth, and L. A. Murakata, "Clear cell carcinoma of the gallbladder. A histological and immunohistochemical study," Pathology Research and Practice, vol. 191, no. 12, pp. 1259-1266, 1995.
69. H. Eken, M. G. Balci, S. Buyukakincak, A. Isik, D. Firat, andO. Cimen, "Rare tumors of the gallbladder: clear cell carcinoma," International Journal of Surgery Case Reports, vol. 9, pp. 65-68, 2015.
70. A.Manouras,M. Genetzakis, E. E. Lagoudianakis et al., "Undifferentiated giant cell type carcinoma of the gallbladder with sarcomatoid dedifferentiation: a case report and review of the literature," Journal of Medical Case Reports, vol. 3, article 6496, 2009.
71. K. B. Badmos, L. Salah Seada, F. Fahad Al Rashid, and H. A. Oreiby, "Undifferentiated spindle-cell carcinoma of the gallbladder: a report of a case, an immunohistochemistry profile, and a review of the literature," Case Reports in Pathology, vol. 2013, Article ID 267194, 3 pages, 2013.
72. E. A. Husain, R. J. Prescott, S. A. Haider et al., "Gallbladder sarcoma: a clinicopathological study of seven cases from the UK and Austria with emphasis on morphological subtypes," DigestiveDiseases and Sciences, vol. 54,no. 2, pp. 395-400, 2009.
73. H.-H. Kim, Y.-H. Hur, E.-H. Jeong et al., "Carcinosarcoma of the gallbladder: report of two cases," Surgery Today, vol. 42, no. 7, pp. 670-675, 2012.
74. K. M. Eltawil, B. I. Gustafsson, M. Kidd, and I. M. Modlin, "Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy," Journal of Clinical Gastroenterology, vol. 44, no. 10, pp. 687-695, 2010.
75. S. Iype, T. A. Mirza, D. J. Propper, S. Bhattacharya, R. M. Feakins, and H. M. Kocher, "Neuroendocrine tumours of the gallbladder: three cases and a review of the literature," Postgraduate Medical Journal, vol. 85, no. 1002, pp. 213-218, 2009.
76. V. Anjaneyulu, G. Shankar-Swarnalatha, and S. C.-S. Rao, "Carcinoid tumor of the gall bladder," Annals of Diagnostic Pathology, vol. 11, no. 2, pp. 113-116, 2007.
77. Y.-P. Zou, W.-M. Li, H.-R. Liu, and N. Li, "Primary carcinoid tumor of the gallbladder: a case report and brief review of the literature," World Journal of Surgical Oncology, vol. 8, article 12, 2010.
78. J. Albores-Saavedra, K. Batich, S.Hossain, D. E.Henson, and A. M. Schwartz, "Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the Surveillance, Epidemiology, and End Results Program," Annals of Diagnostic Pathology, vol. 13, no. 6, pp. 378-383, 2009.
79. D.-M. Kim, S.-O. Yang, H. Y. Han, K. S. Kim, and H. J. Son, "Small cell carcinoma of the gallbladder: 18F-FDG PET/CT imaging features-A case report," Nuclear Medicine and Molecular Imaging, vol. 44, no. 3, pp. 213-216, 2010.
80. N. O. Uribe-Uribe, A. M. Jimenez-Garduño, D. E. Henson, and J. Albores-Saavedra, "Paraneoplastic sensory neuropathy associated with small cell carcinoma of the gallbladder," Annals of Diagnostic Pathology, vol. 13, no. 2, pp. 124-126, 2009.
81. A.Mahipal and S. Gupta, "Small-cell carcinoma of the gallbladder: report of a case and literature review," Case Reports in GI Oncology, vol. 4, no. 4, pp. 135-136, 2011.
82. H. Taniguchi, J. Sakagami, N. Suzuki et al., "Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma," International Journal of Clinical Oncology, vol. 14, no. 2, pp. 167-170, 2009.
83. J. Sakata, Y. Shirai, T. Wakai, Y. Ajioka, and K. Hatakeyama, "Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma," Annals of Surgical Oncology, vol. 17, no. 7, pp. 1831-1840, 2010.
84. C. Pilgrim, V. Usatoff, and P. M. Evans, "A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour," European Journal of Surgical Oncology, vol. 35, no. 9, pp. 903-907, 2009.
85. D. Fuks, J.-M. Regimbeau, P. Pessaux et al., "Is port-site resection necessary in the surgical management of gallbladder cancer?" Journal of Visceral Surgery, vol. 150, no. 4, pp. 277-284, 2013.
86. X. Yi, X. Long, H. Zai, D. Xiao, W. Li, and Y. Li, "Unsuspected gallbladder carcinoma discovered during or after cholecystectomy: focus on appropriate radical re-resection according to the T-stage," Clinical and Translational Oncology, vol. 15, no. 8, pp. 652-658, 2013.
87. L.Hu, B.Wang, X. Liu, and Y. Lv, "Unsuspected gallbladder cancer: a clinical retrospective study," Archives of Iranian Medicine, vol. 16, no. 11, pp. 631-635, 2013.
88. M. D'Hondt, R. Lapointe, Z. Benamira et al., "Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience," European Journal of Surgical Oncology, vol. 39, no. 6, pp. 548-553, 2013.
89. J. C. Roa, O. Tapia, C. Manterola et al., "Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor," Virchows Archiv, vol. 463, pp. 651-661, 2013.
90. D. M. Hari, J. H. Howard, A. M. Leung, C. G. Chui, M.-S. Sim, and A. J. Bilchik, "A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate" HPB, vol. 15, no. 1, pp. 40-48, 2013.
91. D.D. You,H.G. Lee,K. Y. Paik, J. S. Heo, S. H. Choi, and D. W. Choi, "What is an adequate extent of resection for T1 gallbladder cancers?" Annals of Surgery, vol. 247, no. 5, pp. 835-838, 2008.
92. Y. Murakami, K. Uemura, T. Sudo et al., "Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection," Journal of Gastrointestinal Surgery, vol. 15, no. 6, pp. 1007-1016, 2011.
93. H. Nishio, M. Nagino, T. Ebata, Y. Yokoyama, T. Igami, and Y. Nimura, "Aggressive surgery for stage IV gallbladder carcinoma; what are the contraindications?" Journal of Hepato-Biliary-Pancreatic Surgery, vol. 14, no. 4, pp. 351-357, 2007.
94. T. Takada, H. Amano, H. Yasuda et al., "Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma," Cancer, vol. 95, no. 8, pp. 1685-1695, 2002.
95. A. M. Horgan, E. Amir, T. Walter, and J. J. Knox, "Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-Analysis," Journal of Clinical Oncology, vol. 30, no. 16, pp. 1934-1940, 2012.
96. S. J.Wang, A. Lemieux, J. Kalpathy-Cramer et al., "Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer," Journal of Clinical Oncology, vol. 29, no. 35, pp. 4627-4632, 2011.
97. F. Eckel, T. Brunner, and S. Jelic, "Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up," Annals of Oncology, vol. 22, supplement 6, pp. Vi40-vi44, 2011.
98. Capecitabine or Observation after Surgery in Treating Patients with Biliary Tract Cancer, 2015, http://clinicaltrials.gov/show/NCT00363584.
99. Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery, 2015, http://clinicaltrials.gov/ct2/show/NCT01313377term=NCT01313377&rank=1.
100. Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1), 2015, https://clinicaltrials .gov/ct2/show/NCT02170090term=ACTICCA&rank=1.
101. M. A. Ben-David, K. A. Griffith, E. Abu-Isa et al., "Externalbeam radiotherapy for localized extrahepatic cholangiocarcinoma," International Journal of Radiation Oncology Biology Physics, vol. 66, no. 3, pp. 772-779, 2006.
102. M. L. Foo, L. L. Gunderson, C. E. Bender, and S. J. Buskirk, "External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma," International Journal of Radiation Oncology Biology Physics, vol. 39, no. 4, pp. 929-935, 1997.
103. A. R. Sasson, J. P.Hoffman, E. Ross et al., "Trimodality therapy for advanced gallbladder cancer," American Surgeon, vol. 67, no. 3, pp. 277-283, 2001.
104. National Comprehensive Cancer Network (NCCN), "NCCN clinical practice guidelines in oncology," 2014, http://www.nccn .org/professionals/physician gls/f guidelines.asp.
105. A. Sharma, A. D. Dwary, B. K. Mohanti et al., "Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study," Journal of Clinical Oncology, vol. 28, no. 30, pp. 4581-4586, 2010.
106. D. C. Doval, J. S. Sekhon, S.K.Gupta et al., "A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer," British Journal of Cancer, vol. 90, no. 8, pp. 1516-1520, 2004.
107. J. O. Gallardo, B. Rubio, M. Fodor et al., "A phase II study of gemcitabine in gallbladder carcinoma," Annals of Oncology, vol. 12, no. 10, pp. 1403-1406, 2001.
108. J. Reyes-Vidal, J. Gallardo, E. Yáñez et al., "Gemcitabine: gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study 2000-13," Journal of Clinical Oncology, vol. 22, abstract 1095, p. 273, 2003.
109. F. Eckel and R.M. Schmid, "Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials," British Journal of Cancer, vol. 96, no. 6, pp. 896-902, 2007.
110. M. Kajanti and S. Pyrhönen, "Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study," American Journal of Clinical Oncology, vol. 17, article 223, 1994.
111. J. H. Harvey, F. P. Smith, and P. S. Schein, "5-fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract," Journal of Clinical Oncology, vol. 2, no. 11, pp. 1245-1248, 1984.
112. G. Falkson, J. M.MacIntyre, and C. G.Moertel, "Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer," Cancer, vol. 54,no. 6, pp. 965-969, 1984.
113. S. R.Alberts,H.Al-Khatib,M. R.Mahoney et al., "Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a north central cancer treatment group phase II trial," Cancer, vol. 103, no. 1, pp. 111-118, 2005.
114. M. Ducreux, P. Rougier, A. Fandi et al., "Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin," Annals of Oncology, vol. 9, no. 6, pp. 653-656, 1998.
115. J.-S. Chen, Y.-Y. Jan, Y.-C. Lin, H.-M.Wang,W.-C. Chang, and C.-T. Liau, "Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas," Anti-Cancer Drugs, vol. 9, no. 5, pp. 393-397, 1998.
116. P. A. Ellis, A. Norman, A. Hill et al., "Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours," European Journal of Cancer, vol. 31, no. 10, pp. 1594-1598, 1995.
117. J. Y. Cho, Y. H. Paik, Y. S. Chang et al., "Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma," Cancer, vol. 104, no. 12, pp. 2753-2758, 2005.
118. J. J. Knox,D.Hedley, A. Oza et al., "Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial," Journal of Clinical Oncology, vol. 23,no. 10, pp. 2332-2338, 2005.
119. Y. Z. Patt, M. M. Hassan, A. Aguayo et al., "Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma," Cancer, vol. 101, no. 3, pp. 578-586, 2004.
120. O. Nehls, H. Oettle, J. T. Hartmann et al., "Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospectivemulticentre phase II trial," British Journal of Cancer, vol. 98, no. 2, pp. 309-315, 2008.
121. T. W. Kim, H. M. Chang, H. J. Kang et al., "Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer," Annals of Oncology, vol. 14, no. 7, pp. 1115-1120, 2003.
122. M. Penz, G. V. Kornek, M. Raderer et al., "Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer," Annals of Oncology, vol. 12, no. 2, pp. 183-186, 2001.
123. A. D. Wagner, P. Buechner-Steudel, M. Moehler et al., "Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel,multicentre phase-II trials," British Journal of Cancer, vol. 101, no. 11, pp. 1846-1852, 2009.
124. B. Mehrotra, S. Ahmed, and A. Bhargava, "Efficacy of gemcitabine in advanced unresectable biliary tract cancer," Journal of Clinical Oncology, vol. 22, no. 14, supplement, abstract 4259, p. 376, 2004.
125. N. Tsavaris, C. Kosmas, P. Gouveris et al., "Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer," Investigational New Drugs, vol. 22, no. 2, pp. 193-198, 2004.
126. J. W. Valle, H. S. Wasan, D. H. Palmer et al., "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer," The New England Journal ofMedicine, vol. 362, no. 14, pp. 1273-1281, 2010.
127. E. Suzuki, J. Furuse, M. Ikeda et al., "Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases," Oncology, vol. 79, no. 1-2, pp. 39-45, 2010.
128. J. A. Meyerhardt, A. X. Zhu, K. Stuart et al., "Phase-II study of gemcitabine and cisplatin in patientswithmetastatic biliary and gallbladder cancer," Digestive Diseases and Sciences, vol. 53, no. 2, pp. 564-570, 2008.
129. S. Thongprasert, S. Napapan, C. Charoentum, and S. Moonprakan, "Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma," Annals of Oncology, vol. 16, no. 2, pp. 279-281, 2005.
130. G.-W. Lee, J. H. Kang, H.-G. Kim, J.-S. Lee, J.-S. Lee, and J.-S. Jang, "Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma," American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 29,no. 2, pp. 127-131, 2006.
131. S. T.Kim, J.O. Park, J. Lee et al., "APhase II study of gemcitabine and cisplatin in advanced biliary tract cancer," Cancer, vol. 106, no. 6, pp. 1339-1346, 2006.
132. J.Harder, B. Riecken,O.Kummer et al., "Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer," British Journal of Cancer, vol. 95, no. 7, pp. 848-852, 2006.
133. T. André, C. Tournigand, O. Rosmorduc et al., "Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study," Annals of Oncology, vol. 15, no. 9, pp. 1339-1343, 2004.
134. N. Gebbia, F. Verderame, R. Di Leo et al., "A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers," Proceedings of the American Society of Clinical Oncology, vol. 23, p. 4132, 2005.
135. R. P. Riechelmann, C. A. Townsley, S. N. Chin, G. R. Pond, and J. J. Knox, "Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer," Cancer, vol. 110, no. 6, pp. 1307-1312, 2007.
136. R.V. Iyer, J. Gibbs, B. Kuvshinoffet al., "Aphase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study," Annals of SurgicalOncology, vol. 14,no. 11,pp. 3202-3209, 2007.
137. P. K. Julka, T. Puri, and G. K. Rath, "A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma," Hepatobiliary & Pancreatic Diseases International, vol. 5, no. 1, pp. 110-114, 2006.
138. D. V. Jones Jr., R. Lozano, A. Hoque, A. Markowitz, and Y. Z. Patt, "Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas," Journal of Clinical Oncology, vol. 14,no. 8, pp. 2306-2310, 1996.
139. S. R. Alberts, J. R. Sande, N. R. Foster et al., "Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943," Journal of Gastrointestinal Cancer, vol. 38, no. 2-4, pp. 87-94, 2007.
140. P. Papakostas, C. Kouroussis, N. Androulakis et al., "First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study," European Journal of Cancer, vol. 37, no. 15, pp. 1833-1838, 2001.
141. P. M. Sanz-Altamira, E. O'Reilly, K. E. Stuart et al., "A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma," Annals of Oncology, vol. 12,no. 4, pp. 501-504, 2001.
142. A. Sancho, G. Lopez-Vivanco, I. D. De Concuera et al., "Oxaliplatin and capecitabine after gemcitabine failure in patientswith advanced, pancreatic, biliary, and gallbladder adenocarcinoma," Journal of Clinical Oncology, vol. 26, no. 15, p. 665s, 2008.
143. B. G. Müller, X. De Aretxabala, and M. G. Domingo, "A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done," in American Society of Clinical Oncology Educational Book, vol. 34, pp. e165-e170, American Society of Clinical Oncology, Alexandria, Va, USA, 2014.
144. A. F. Hezel, V. Deshpande, and A. X. Zhu, "Genetics of biliary tract cancers and emerging targeted therapies," Journal of Clinical Oncology, vol. 28, no. 21, pp. 3531-3540, 2010.
145. A. B. El-Khoueiry, C. J. Rankin, E. Ben-Josef et al., "SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma," Investigational New Drugs, vol. 30, no. 4, pp. 1646-1651, 2012.
146. J. H. Yi, S. Thongprasert, J. Lee et al., "A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study," European Journal of Cancer, vol. 48, no. 2, pp. 196-201, 2012.
147. R. K. Ramanathan, C. P. Belani, D. A. Singh et al., "A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer," Cancer Chemotherapy and Pharmacology, vol. 64, no. 4, pp. 777-783, 2009.
148. J. Peck, L.Wei, M. Zalupski, B. O'Neil,M. Villalona Calero, and T. Bekaii-Saab, "HER2/neu may not be an interesting target in biliary cancers: results of an early phase II Studywith Lapatinib," Oncology, vol. 82, no. 3, pp. 175-179, 2012.
149. M. R. Costello, N. J. Meropol, C. S. Denlinger et al., "A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135)," Journal of Clinical Oncology, vol. 27, supplement, abstract e15605, 2009, ASCO Annual Meeting.
150. T. Bekaii-Saab, M. A. Phelps, X. Li et al., "Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers," Journal of Clinical Oncology, vol. 29, no. 17, pp. 2357-2363, 2011.
151. S. J. Lubner, M. R. Mahoney, J. L. Kolesar et al., "Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study," Journal of Clinical Oncology, vol. 28, no. 21, pp. 3491-3497, 2010.
152. K. S. Rohrberg, R. K. Olesen, P. Pfeiffer et al., "Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers,"ActaOncologica, vol. 51,no. 2, pp. 234-242, 2012.
153. D. Malka, T. Trarbach, L. Fartoux et al., "A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the firstline treatment of advanced biliary cancer: interim analysis of the BINGO trial," Journal of Clinical Oncology, vol. 27, no. 15, supplement, abstract 4520, 2009.
154. B. Gruenberger, J. Schueller, U. Heubrandtner et al., "Cetuximab, gemcitabine, and oxaliplatin in patientswith unresectable advanced or metastatic biliary tract cancer: a phase 2 study,"The Lancet Oncology, vol. 11, no. 12, pp. 1142-1148, 2010.
155. L. T. Chen, J. S. Chen, Y. Chao et al., "KRAS mutation statusstratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): the TCOG T1210 trial," Journal of Clinical Oncology, vol. 31, supplement, abstract 4018, 2013.
156. A. X. Zhu, J. A. Meyerhardt, L. S. Blaszkowsky et al., "Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancer and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study," The Lancet Oncology, vol. 11, no. 1, pp. 48-54, 2010.
157. A. J. Ocean, P. Christos, J. A. Sparano et al., "Phase II trial of the ribonucleotide reductase inhibitor 3-Aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer," Cancer Chemotherapy and Pharmacology, vol. 68, no. 2, pp. 379-388, 2011.
158. K. Schuette, E. Kettner, S. Al-Batran et al., "Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer," Journal of Clinical Oncology, vol. 27, supplement, abstract e15622, 2009.
159. J. Lee, S. H. Park, H.-M. Chang et al., "Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study," The Lancet Oncology, vol. 13, no. 2, pp. 181-188, 2012.
160. S. Misra, A. Chaturvedi, N. C. Misra, and I. D. Sharma, "Carcinoma of the gallbladder," The Lancet Oncology, vol. 4, no. 3, pp. 167-176, 2003.
161. L.M.Mazer,H. F. Losada, R. M. Chaudhry et al., "Tumour characteristics and survival analysis of incidental versus suspected gallbladder carcinoma," Journal of Gastrointestinal Surgery, vol. 16, no. 7, pp. 1311-1317, 2012.
162. K.-I. Okada, H. Kijima, T. Imaizumi et al., "Wall-invasion pattern correlates with survival of patients with gallbladder adenocarcinoma," Anticancer Research, vol. 29, no. 2, pp. 685-692, 2009.
163. G. Zhai, K. Yan, X. Ji et al., "LAPTM4B Allele 2 Is a Marker of Poor Prognosis for Gallbladder Carcinoma," PLoS ONE, vol. 7, no. 9, Article IDe45290, 2012.
164. M.G.McNamara, C.Metran-Nascente, and J. J.Knox, "State-ofthe-Art in the management of locally advanced and metastatic gallbladder cancer," Current Opinion in Oncology, vol. 25, no. 4, pp. 425-431, 2013.
165. R. Kanthan, J. M. Radhi, and S. C. Kanthan, "Gallbladder carcinomas: an immunoprognostic evaluation of P53, Bcl-2, CEA and alpha-fetoprotein," Canadian Journal of Gastroenterology, vol. 14, no. 3, pp. 181-184, 2000.
166. S.-Y.Choi, Y. S. Jo, S.-M.Huang et al., "L1 cell adhesionmolecule as a novel independent poor prognostic factor in gallbladder carcinoma," Human Pathology, vol. 42, no. 10, pp. 1476-1483, 2011.
167. Y. Zhang, Y. Huang, and M. Qin, "Tumour-infiltrating FoxP3+ and IL-17-producing T cells affect the progression and prognosis of gallbladder carcinoma after surgery," Scandinavian Journal of Immunology, vol. 78, no. 6, pp. 516-522, 2013.
168. S. Prince, A. Zeidman, Y. Dekel, E. Ram, and R. Koren, "Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathologic variables," American Journal of Clinical Pathology, vol. 129, no. 3, pp. 424-429, 2008.
169. J. Li, Z.-L. Yang, X. Ren et al., "ACE2 and FZD1 are prognosis markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of gallbladder," Journal ofMolecularHistology, vol. 45, no. 1, pp. 47-57, 2014.